经导管主动脉瓣生物瓣外科取出:球囊扩张 vs 自膨胀装置
基于STS国家数据库2016–2019年483例TAVR瓣膜外科取出患者,比较球囊扩张(330例)与自膨胀(153例)装置的临床结局。两组30天死亡率无差异,总体为18%;自膨胀组升主动脉置换更常见(22% vs 9%)。孤立外科主动脉瓣置换患者O/E死亡比为2.2,提示TAVR取出风险较高。
要点
- TAVR取出总体30天死亡率为18%,球囊扩张与自膨胀装置间无差异。
- 自膨胀装置患者升主动脉置换率更高(22% vs 9%,P<.001)。
- 孤立外科主动脉瓣置换患者O/E死亡比为2.2,提示取出风险高于预测。
核心结论
- 球囊扩张与自膨胀TAVR装置取出后的结局相当,但自膨胀装置患者升主动脉置换更频繁。
- 接受TAVR的年轻患者应被告知未来瓣膜取出可能伴随较高O/E比和频繁的同期手术风险。
研究设计与样本
- 回顾性队列研究,使用STS国家数据库查询2016–2019年TAVR瓣膜外科取出病例。
- 共纳入483例有明确取出瓣膜类型的患者,其中球囊扩张330例(68%),自膨胀153例(32%)。
主要发现
- 平均年龄72.8岁,女性占38%,51%为NYHA III–IV级症状。
- 63%的患者在TAVR取出时需同期其他手术,包括主动脉修复27%、二尖瓣手术22%、冠状动脉旁路移植15%、三尖瓣手术7%。
- 自膨胀装置组升主动脉置换率高于球囊扩张组(22% vs 9%;P < .001),主动脉根部置换率两组相似(19% vs 24%;P = .22)。
- 总体30天死亡率为18%,两组死亡率和其它主要并发症无差异。
- 157例孤立外科主动脉瓣置换且具备STS预测死亡风险评分的患者中,观察与预期(O/E)死亡比为2.2。
临床怎么用
- TAVR瓣膜取出手术风险高,需充分评估同期手术需求,尤其自膨胀装置患者注意升主动脉处理。
- 对年轻TAVR患者应告知未来瓣膜取出可能伴随较高O/E死亡比和频繁同期手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the rapid adoption of transcatheter aortic replacement (TAVR), surgical TAVR valve explantation (TAVR-explant) and the clinical impact of explanted TAVR device type are not well described. METHODS: TAVR-explant from 2016 to 2019 was queried using the Society of Thoracic Surgeons (STS) National Database. A total of 483 patients with documented explanted valve type, consisting of 330 (68%) patients with balloon-expandable and 153 (32%) patients with self-expandable devices, were identified. The primary outcome was 30-day mortality. The secondary outcome was the need for any simultaneous procedures with TAVR-explant. RESULTS: The mean age was 72.8 years, 38% of the patients were female, and 51% demonstrated New York Heart Association functional class III to IV symptoms. During TAVR-explant, 63% of patients required other simultaneous procedures, including aortic repair (27%), mitral procedures (22%), coronary artery bypass grafting (15%), and tricuspid procedures (7%). Patients with a self-expandable device underwent more frequent ascending aortic replacement (22% vs 9%; P < .001) than those with a balloon-expandable device, whereas the aortic root replacement rate was similar (19% vs 24%; P = .22). The overall 30-day mortality was 18% without differences in the mortality or other major complications between the groups. Of the 157 patients with isolated surgical aortic valve replacement and available STS predicted risk of mortality score, the observed-to-expected (O/E) mortality ratio was 2.2. CONCLUSIONS: The TAVR-explant outcomes were comparable between patients with balloon-expandable devices and patients with self-expandable devices, whereas ascending aortic replacement was observed more frequently in patients with self-expandable devices. Younger patients undergoing TAVR should be informed of the future TAVR-explant risk that may accompany a higher O/E ratio and frequent morbid concurrent procedures.
引用
- Fukuhara S, Nguyen CTN, Yang B, et al. Surgical Explantation of Transcatheter Aortic Bioprostheses: Balloon vs Self-Expandable Devices. Ann Thorac Surg. 2021. PMID: 33545150. doi:10.1016/j.athoracsur.2021.01.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。